tetano
Editor, Senior Moderator
lin Kidney J
. 2022 Jul 26;15(10):1856-1864.
doi: 10.1093/ckj/sfac169. eCollection 2022 Oct.
Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
Borja Quiroga[SUP] 1 [/SUP], María José Soler[SUP] 2 3 [/SUP], Alberto Ortiz[SUP] 3 4 [/SUP], Carlos Jesús Jaravaca Mantecón[SUP] 5 [/SUP], Nathasha Nava Pérez[SUP] 5 [/SUP], Marta Serra Martín[SUP] 6 [/SUP], Yurika Sato[SUP] 6 [/SUP], Antonio José Marin Franco[SUP] 7 [/SUP], Diana Flor Pazmiño Zambrano[SUP] 7 [/SUP], Rafael Lucena Valverde[SUP] 8 [/SUP], Mayra Ortega Diaz[SUP] 8 [/SUP], Carmen Calderón González[SUP] 9 [/SUP], Juan Manuel Cazorla López[SUP] 10 [/SUP], Mónica Pereira[SUP] 4 [/SUP], Emilio González Parra[SUP] 4 [/SUP], Ana Sánchez Horrillo[SUP] 1 [/SUP], Carmen Sánchez González[SUP] 1 [/SUP], Néstor Toapanta[SUP] 2 [/SUP], Secundino Cigarrán Guldris[SUP] 11 [/SUP], Rosa Sánchez Hernández[SUP] 12 [/SUP], Soledad Pizarro Sánchez[SUP] 13 [/SUP], María Muñiz Rincón[SUP] 14 [/SUP], Nuria Garcia-Fernández[SUP] 15 [/SUP], Natalia Blanco Castro[SUP] 16 [/SUP], Rocío Collantes Mateo[SUP] 17 [/SUP], Manuel Augusto Quiroz Morales[SUP] 18 [/SUP], Beatriz Escamilla-Cabrera[SUP] 19 [/SUP], Isabel Berdud Godoy[SUP] 20 [/SUP], Beatriz Gil-Casares Casanova[SUP] 21 [/SUP], Alba Leyva[SUP] 22 [/SUP], José Rojas[SUP] 22 [/SUP], Ron T Gansevoort[SUP] 23 [/SUP], Patricia de Sequera[SUP] 3 8 [/SUP], SENCOVAC collaborative network
Collaborators, Affiliations
Abstract
Background: Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose.
Methods: This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed.
Results: A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001).
Conclusions: In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.
Keywords: COVID-19; SARS-CoV-2; booster; hemodialysis; vaccination.
. 2022 Jul 26;15(10):1856-1864.
doi: 10.1093/ckj/sfac169. eCollection 2022 Oct.
Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
Borja Quiroga[SUP] 1 [/SUP], María José Soler[SUP] 2 3 [/SUP], Alberto Ortiz[SUP] 3 4 [/SUP], Carlos Jesús Jaravaca Mantecón[SUP] 5 [/SUP], Nathasha Nava Pérez[SUP] 5 [/SUP], Marta Serra Martín[SUP] 6 [/SUP], Yurika Sato[SUP] 6 [/SUP], Antonio José Marin Franco[SUP] 7 [/SUP], Diana Flor Pazmiño Zambrano[SUP] 7 [/SUP], Rafael Lucena Valverde[SUP] 8 [/SUP], Mayra Ortega Diaz[SUP] 8 [/SUP], Carmen Calderón González[SUP] 9 [/SUP], Juan Manuel Cazorla López[SUP] 10 [/SUP], Mónica Pereira[SUP] 4 [/SUP], Emilio González Parra[SUP] 4 [/SUP], Ana Sánchez Horrillo[SUP] 1 [/SUP], Carmen Sánchez González[SUP] 1 [/SUP], Néstor Toapanta[SUP] 2 [/SUP], Secundino Cigarrán Guldris[SUP] 11 [/SUP], Rosa Sánchez Hernández[SUP] 12 [/SUP], Soledad Pizarro Sánchez[SUP] 13 [/SUP], María Muñiz Rincón[SUP] 14 [/SUP], Nuria Garcia-Fernández[SUP] 15 [/SUP], Natalia Blanco Castro[SUP] 16 [/SUP], Rocío Collantes Mateo[SUP] 17 [/SUP], Manuel Augusto Quiroz Morales[SUP] 18 [/SUP], Beatriz Escamilla-Cabrera[SUP] 19 [/SUP], Isabel Berdud Godoy[SUP] 20 [/SUP], Beatriz Gil-Casares Casanova[SUP] 21 [/SUP], Alba Leyva[SUP] 22 [/SUP], José Rojas[SUP] 22 [/SUP], Ron T Gansevoort[SUP] 23 [/SUP], Patricia de Sequera[SUP] 3 8 [/SUP], SENCOVAC collaborative network
Collaborators, Affiliations
- PMID: 36147708
- PMCID: PMC9384616
- DOI: 10.1093/ckj/sfac169
Abstract
Background: Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose.
Methods: This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed.
Results: A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001).
Conclusions: In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.
Keywords: COVID-19; SARS-CoV-2; booster; hemodialysis; vaccination.